Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Carcinoma, Renal Cell 11Melanoma 10Carcinoma, Hepatocellular 7Brain Neoplasms 6Leukemia, Myeloid, Acute 5Glioblastoma 5Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myelomonocytic, Acute 4Gliosarcoma 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Rectal Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Liver Neoplasms 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Leukemia, Eosinophilic, Acute 3Leukemia, Basophilic, Acute 3Hemangiosarcoma 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Blast Crisis 3

Interventions

fludarabine phosphate 3Cyclophosphamide 3Antilymphocyte Serum 3tipifarnib 2Radiotherapy 2Peripheral Blood Stem Cell Transplantation 2Isotretinoin 2Cytarabine 2Busulfan 2Biopsy 2trametinib 1thymoglobulin 1omipalisib 1Vorinostat 1Transplantation 1Tacrolimus 1Sorafenib 1Radiation 1Polymerase Chain Reaction 1Mycophenolic Acid 1Methylprednisolone 1Methotrexate 1Mercaptopurine 1Melphalan 1MK 2206 1Flow Cytometry 1Filgrastim 1Cord Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelomonocytic, Juvenile × Sorafenib × Clear all
NCT01445080 2021-02-02

Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
70 enrolled 26 charts
LymphoidMyeloidOther hematologic neoplasm

Blast Crisis, Recurrence, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡